Comparison of risk prediction models in infarct-related cardiogenic shock.

Acute myocardial infarction Outcome Prognosis Risk models Scores   Cardiogenic shock

Journal

European heart journal. Acute cardiovascular care
ISSN: 2048-8734
Titre abrégé: Eur Heart J Acute Cardiovasc Care
Pays: England
ID NLM: 101591369

Informations de publication

Date de publication:
27 Oct 2021
Historique:
received: 17 03 2021
revised: 25 05 2021
accepted: 22 06 2021
pubmed: 17 9 2021
medline: 25 11 2021
entrez: 16 9 2021
Statut: ppublish

Résumé

Several prediction models have been developed to allow accurate risk assessment and provide better treatment guidance in patients with infarct-related cardiogenic shock (CS). However, comparative data between these models are still scarce. The objective of the study is to externally validate different risk prediction models in infarct-related CS and compare their predictive value in the early clinical course. The Simplified Acute Physiology Score (SAPS) II Score, the CardShock score, the IABP-SHOCK II score, and the Society for Cardiovascular Angiography and Intervention (SCAI) classification were each externally validated in a total of 1055 patients with infarct-related CS enrolled into the randomized CULPRIT-SHOCK trial or the corresponding registry. The primary outcome was 30-day all-cause mortality. Discriminative power was assessed by comparing the area under the curves (AUC) in case of continuous scores. In direct comparison of the continuous scores in a total of 161 patients, the IABP-SHOCK II score revealed best discrimination [area under the curve (AUC = 0.74)], followed by the CardShock score (AUC = 0.69) and the SAPS II score, giving only moderate discrimination (AUC = 0.63). All of the three scores revealed acceptable calibration by Hosmer-Lemeshow test. The SCAI classification as a categorical predictive model displayed good prognostic assessment for the highest risk group (Stage E) but showed poor discrimination between Stages C and D with respect to short-term-mortality. Based on the present findings, the IABP-SHOCK II score appears to be the most suitable of the examined models for immediate risk prediction in infarct-related CS. Prospective evaluation of the models, further modification, or even development of new scores might be necessary to reach higher levels of discrimination.

Identifiants

pubmed: 34529043
pii: 6371144
doi: 10.1093/ehjacc/zuab054
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

890-897

Subventions

Organisme : German Heart Research Foundation
Organisme : European Union
Organisme : DZHK

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Auteurs

Anne Freund (A)

Department of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig, Strümpellstr. 39, D-04289 Leipzig, Germany.
Leipzig Heart Institute, Leipzig, Germany.
German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Lübeck, Germany.

Janine Pöss (J)

Department of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig, Strümpellstr. 39, D-04289 Leipzig, Germany.

Suzanne de Waha-Thiele (S)

Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

Roza Meyer-Saraei (R)

German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Lübeck, Germany.
University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.

Georg Fuernau (G)

German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Lübeck, Germany.
University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.

Ingo Eitel (I)

German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Lübeck, Germany.
University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.

Hans-Josef Feistritzer (HJ)

Department of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig, Strümpellstr. 39, D-04289 Leipzig, Germany.
Leipzig Heart Institute, Leipzig, Germany.

Maria Rubini (M)

Department of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig, Strümpellstr. 39, D-04289 Leipzig, Germany.
Leipzig Heart Institute, Leipzig, Germany.

Kurt Huber (K)

Department of Cardiology, Wilhelminenspital, and Sigmund Freud University, Medical School, Vienna, Austria.

Stephan Windecker (S)

University of Bern, Inselspital, Bern, Switzerland.

Gilles Montalescot (G)

Sorbonne Université, ACTION Study Group, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France.

Keith Oldroyd (K)

Golden Jubilee National Hospital and University of Glasgow, Scotland, UK.

Marko Noc (M)

University Medical Center Ljubljana, Ljubljana, Slovenia.

Uwe Zeymer (U)

Medizinische Klinik B, Klinikum Ludwigshafen, Germany.
Stiftung Institut für Herzinfarktforschung (Foundation IHF), Ludwigshafen, Germany.

Taoufik Ouarrak (T)

Stiftung Institut für Herzinfarktforschung (Foundation IHF), Ludwigshafen, Germany.

Steffen Schneider (S)

Stiftung Institut für Herzinfarktforschung (Foundation IHF), Ludwigshafen, Germany.

David A Baran (DA)

Sentara Heart Hospital, Advanced Heart Failure Center, Norfolk, USA.

Steffen Desch (S)

Department of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig, Strümpellstr. 39, D-04289 Leipzig, Germany.
Leipzig Heart Institute, Leipzig, Germany.
German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Lübeck, Germany.
University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.

Holger Thiele (H)

Department of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig, Strümpellstr. 39, D-04289 Leipzig, Germany.
Leipzig Heart Institute, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH